The effect of decitabine on megakaryocyte maturation and platelet release

Thrombosis and Haemostasis

Volumn 106, Issue 2, 2011, Pages 337-343

  Wang, Jianhui ^a   Yi, Zanhua ^a   Wang, Shiyang ^a   Li, Zongdong ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Decitabine; Myelodysplastic syndromes; Thrombocytopenia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLCHOLINESTERASE; CD34 ANTIGEN; FIBRINOGEN RECEPTOR; RECOMBINANT THROMBOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MEGAKARYOBLAST; MEGAKARYOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; THROMBOCYTE RELEASE REACTION; UMBILICAL CORD BLOOD;

ANIMALS; AZACITIDINE; BLOOD PLATELETS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; DNA METHYLATION; FETAL BLOOD; HUMANS; MEGAKARYOCYTES; MICE; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; POLYPLOIDY; THROMBOCYTOPENIA; THROMBOPOIESIS; UP-REGULATION;

EID: 79961051183     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-11-0744     Document Type: Article

References (31)

1. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109: 1705-1714.
2. Steensma DP. Myelodysplasia, megakaryocytes, and methylation. Leuk Res 2004; 28: 775-776.
3. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 2010; 6: 445-455.
4. Lee ST, Jang JH, Suh HC, et al. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol 2001; 68: 237-245.
5. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557.
6. Rosenfeld CS, Zeigler ZR, Shadduck RK, et al. Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol 1997; 20: 189-192.
7. Platzbecker U, Haase M, Herbst R, et al. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study. Br J Haematol 2005; 128: 625-630.
8. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3: 807-817.
9. de Vos D, van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005; 84 (Suppl 1): 3-8.
10. Issa JP. Decitabine. Curr Opin Oncol 2003; 15: 446-451.
11. Bonifer C, Lefevre P, Tagoh H. The regulation of chromatin and DNA-methylation patterns in blood cell development. Curr Top Microbiol Immunol 2006; 310: 1-12.
12. Hennessy BT, Garcia-Manero G, Kantarjian HM, et al. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs 2003; 12: 1985-1993.
13. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006; 20: 1-13.
14. Gao S, Skeldal S, Krogdahl A, et al. CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines. Thromb Haemost 2005; 94: 651-660.
15. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102: 3865-3870.
16. Pecci A, Malara A, Badalucco S, et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009; 102: 90-96.
17. van den Oudenrijn S, von dem Borne AE, de Haas M. Differences in megakaryocyte expansion potential between CD34(+) stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp Hematol 2000; 28: 1054-1061.
18. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
19. Oakeley EJ, Schmitt F, Jost JP. Quantification of 5-methylcytosine in DNA by the chloroacetaldehyde reaction. Biotechniques 1999; 27: 744-752.
20. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74: 521-525.
21. Vainchenker W, Methia N, Debili N, et al. C-mpl, the thrombopoietin receptor. Thromb Haemost 1995; 74: 526-528.
22. Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb Haemost 2008; 99: 863-873.
23. Teofili L, Martini M, Di Mario A, et al. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 2001; 98: 495-497.
24. Kanaji S, Kanaji T, Jacquelin B, et al. Thrombopoietin initiates demethylationbased transcription of GP6 during megakaryocyte differentiation. Blood 2005; 105: 3888-3892.
25. Gandhi MJ, Drachman JG, Reems JA, et al. A novel strategy for generating platelet- like fragments from megakaryocytic cell lines and human progenitor cells. Blood Cells Mol Dis 2005; 35: 70-73.
26. Kaminska J, Klimczak-Jajor E, Skierski J, et al. Effects of inhibitor of Src kinases, SU6656, on differentiation of megakaryocytic progenitors and activity of alpha1,6-fucosyltransferase. Acta Biochim Pol 2008; 55: 499-506.
27. Lannutti BJ, Blake N, Gandhi MJ, et al. Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. Blood 2005; 105: 3875-3878.
28. Bluteau D, Lordier L, Di Stefano A, et al. Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009; 7 (Suppl 1): 227-234.
29. van den Bosch J, Lubbert M, Verhoef G, et al. The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004; 28: 785-790.
30. Hofmann WK, Kalina U, Koschmieder S, et al. Defective megakaryocytic development in myelodysplastic syndromes. Leuk Lymphoma 2000; 38: 13-19.
31. Kalina U, Hofmann WK, Koschmieder S, et al. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 2000; 28: 1158-1163.